HealthCare Middle East & Africa Magazine
No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
GSK
-
GSK acquires Syndivia’s preclinical ADC for prostate cancer in US$357M deal
Each year, about 1.4 million men worldwide receive a prostate cancer diagnosis, and nearly 20% of these cases progress to advanced, metastatic, and castration-resistant disease within five years.
-
GSK’s Shingrix vaccine approved in China to prevent shingles in vulnerable patients
This vaccine is authorized for preventing shingles, or herpes zoster, in adults aged 18 and older who face a higher risk due to compromised immune systems caused by disease or medical treatments.
-
GSK names Luke Miels as new CEO to succeed Emma Walmsley in 2026
Emma Walmsley will officially step down as CEO on December 31, 2025, but she will remain with GSK through September 2026 to aid the transition.
-
GSK to invest US$30B in U.S. amid UK life sciences concerns
Out of the total investment, US$1.2 billion is allocated specifically for advanced manufacturing, artificial intelligence (AI), and digital technology initiatives.
-
GSK relaunches oncology in India with Jemperli & Zejula, targets growing cancer market
GSK’s oncology efforts are part of a broader strategic shift toward developing specialty and super-specialty drug portfolios in India.
-
FDA expedites review of new GSK antibiotic for drug-resistant gonorrhoea
Once approved, gepotidacin would be prescribed for uncomplicated urogenital gonorrhoea in patients aged 12 years and older who weigh at least 45 kilograms.
-
GSK completes US$2B acquisition of Efimosfermin Alfa for serious liver diseases
GSK’s acquisition of Boston Pharmaceuticals’ BP Asset IX, announced in May 2025, expanded its portfolio to include treatments for liver, lung, and kidney diseases.
-
NHS England to launch world-first “Trojan Horse” therapy for multiple myeloma
Belantamab mafodotin is an antibody-drug conjugate that works by specifically targeting and binding to cancer cells.
-
Theravance Biopharma sells remaining Trelegy royalty interest to GSK for US$225 million
Despite that sale, Theravance retained rights to receive 85% of Trelegy royalties on sales from 2029 onward outside the U.S., and from 2031 in the U.S.
-
Japan approves GSK’s Blenrep combinations for multiple myeloma
These studies evaluated Blenrep combined with either bortezomib plus dexamethasone (BVd) or pomalidomide plus dexamethasone (BPd) in patients who had previously undergone at least one treatment for refractory multiple myeloma .